# Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

> **NCT04549467** · PHASE4 · COMPLETED · sponsor: **Fundacion IDEAA** · enrollment: 244 (actual)

## Conditions studied

- Hiv
- HIV-1-infection

## Interventions

- **DRUG:** Lamivudine 300 MG
- **DRUG:** Emtricitabine / Tenofovir Disoproxil Pill

## Key facts

- **NCT ID:** NCT04549467
- **Lead sponsor:** Fundacion IDEAA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-17
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04549467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04549467, "Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04549467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*